Rachel Webster

Head of Oncology & Biosimilars. @ClarivateHealth. Experienced oncology expert. Providing best-in-class market research and insights in oncology drug markets.

[Rachel Webster @RachelMWebster1]

Hot off the press! Find out more about the small-cell lung cancer pipeline and market from DRG experts @NatRevDrugDisc @RWebsterDRG #DRGOncology #SCLC https://t.co/aZtsIMq80e https://t.co/lrCGtYZKB8

[Rachel Webster @RachelMWebster1]

Check out my latest article: The small-cell lung cancer drug market
https://t.co/AnnLTDV8rK via @LinkedIn

[Rachel Webster @RachelMWebster1]

Check out our latest article: DRG expert insights on tumour-agnostic therapies https://t.co/GYKAAXbXqn via @LinkedIn

[Rachel Webster @RachelMWebster1]

More analysis and insights from @DRGinsights experts @KhurramOncology @am_looney @RWebsterDRG Find out more about tumour-agnostic therapies #DRGOncology

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Find out about the pipeline and market for tumour-agnostic therapies in this article published today by @RWebsterDRG and colleagues https://t.co/GAR3c66gfg #precisionmedicine

[Rachel Webster @RachelMWebster1]

The approval (and uptake) of 9 drugs
since 2017 is fuelling rapid growth of
the AML market. These drugs are
expected to occupy 85% of the market in
2028. Find out more @DRGinsights #DRGOncology Read
our latest @NatRevDrugDisc article https://t.co/68I4rStkEx

[Megan Cully @megan_cully]

Despite the small number of patients (2% of cancers), drugs for multiple myeloma were worth nearly $14B in 2017. @DRGinsights explains drivers and how that market will change in the next 10 years @NatRevDrugDisc https://t.co/HhCvER7ITy

[Andrew Merron @Andrew_Merron]

sBLAs for #Keytruda dosing every 6 weeks have been accepted by the #FDA. In the US Keytruda is currently dosed every 3 weeks and #Opdivo is dosed every 2 weeks or every 4 weeks. Convenience of dosing schedules can have a big influence on drug selection! #DRGOncology

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in the R&D landscape for antibody-drug conjugates such as the one involved in AstraZeneca's multi-billion dollar collaboration with Daiichi Sankyo, here's a recent review https://t.co/GT34IyDXnB

[Nature Reviews Drug Discovery @NatRevDrugDisc]

This new article analyses the pipeline and market for drugs to treat multiple myeloma https://t.co/VbBjrt51bK

[Rachel Webster @RachelMWebster1]

Read our latest @NatRevDrugDisc article on
the Multiple Myeloma Drug Market. https://t.co/1SaJJk3EOn
@RWebsterDRG #DRGOncology For more expert insights check out https://t.co/uCQOkOLqp8 https://t.co/h6X7YaJxYy

[Andrew Merron @Andrew_Merron]

What does #DRGOncology expect for the #oncology market in 2019? Check out our #video prediction here: https://t.co/4fG8MzbGXK

[Andrew Merron @Andrew_Merron]

CAR T-Cell Therapies In The EU5: What Can We Expect From Payers? Latest insights from #DRGOncology experts @RWebsterDRG find the article here: https://t.co/jYNYdQrSC2

[Andrew Merron @Andrew_Merron]

ESMO 2018: Expanding Horizons in Advanced Breast Cancer. More insights from the #DRGOncology experts. Check out more insights at https://t.co/jYNYdQrSC2 https://t.co/r1DC4QD5HE

[Andrew Merron @Andrew_Merron]

DRG's @RWebsterDRG https://t.co/ick71zVuKj., D.Phil discusses the rapid growth of the oncology drug market and advances in oncology treatments with PharmaVOICE. #DRGOncology Read more here:
https://t.co/7Gl4R95nNm

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Analysis of the hepatocellular carcinoma pipeline and market https://t.co/X7XCX8CgJB

[Rachel Webster @RachelMWebster1]

Read about the latest news and our expert analysis of the #Hepatocellular Carcinoma Market in our latest @NatRevDrugDis
article @JNBDawkins @RWebsterDRG #DRGOncology

[Andrew Merron @Andrew_Merron]

Working in oncology? Subscribe to https://t.co/jYNYdQrSC2 for free and receive thought #leadership, #infographics, updates, and #opinions on the #oncology landscape. @DRGinsights #DRGOncology

[Joshua Dawkins @JBNDawkins]

Big blow to RCC and Opdivo/Yeroy in EU. "They didn't feel we'd demonstrated the contribution of components sufficiently". Is it Re no mono arm? Favourable risk data? Shock given it's 37% reduced risk of DEATH & 15% higher response! #DRGOncology $BMY #KCSM
https://t.co/KEDTwIom4J